Home

• What is Hepatitis C?
  
• Are You at Risk?
  
• Get Tested
  
• Living with Hepatitis C
  
• Diagnosis
  
• Treatment
  
• Resources
• Hepatitis C and Alcohol
• Find OTP Treatment Facility
• Hepatitis C Support Groups
• Schedule Training at Your Facility
• Accessibility
• Viewer
• Disclaimer

About Us

• Our Goal
  
• HHS
  
• SAMHSA
  
• CSAT
  
• AATOD
  
• Hepatitis C Association
  
• Funding

Calendar

Research/Articles

• Response to Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis C in Hispanics Compared to Non-Hispanic Whites
• Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C
• Hypothyroidism In Women Associated With Liver Cancer
• Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
  
• Promising Early Results from the First Clinical Trial of a Combination Regimen of two Oral Antiviral Agents for Chronic Hepatitis C
• Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
• Hepatitis Outbreaks Caused by Carelessness
  
• Sustained Virological Response Reduces Incidence of Onset of Type 2 Diabetes in Chronic Hepatitis C
  
• Romark Announces Presentation of New Data for Controlled Release Nitazoxanide
  in Chronic Hepatitis C
• Nitazoxanide: Beyond Parasites toward a Novel Agent for Hepatitis C
• Vitamin D Deficiency Common in Patients with IBD, Chronic Liver Disease
• Hepatitis C and Hepatocellular Carcinoma: Grist for the Mill
• Rare Birds in North America: Acute Hepatitis C Cohorts
• Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse
• Hepatitis B: A “GLOBAL” Health Challenge
• FDA Approves Nexavar for Patients with Inoperable Liver Cancer
• CDC Report Examines High-Risk Behaviors Associated with HIV Among IDUs

Library

• Adult Viral Hepatitis Coordinators
• Americans with Disabilities Act
• AASLD PRACTICE GUIDELINE
• Aspects of HIV and HCV
• The Biopsy Report: A Patient's Guide
• Books
• Burden of Hepatitis C Infection: Realities and Challenges
• CAM and Hepatitis C: A Focus on Herbal Supplements
• Care for Patients Coinfected with HIV-HCV: New Consensus Guidelines from an International Panel
• Chronic Hepatitis C in the Latino population
• Chronic hepatitis C in Minority Populations
• Chronic Hepatitis C During Pregnancy
• Counseling Guidelines
• Diet and Your Liver
• Disability Benefits Available from the Social Security Administration
• Effects of Pegylated Interferon Alfa-2b on the Pharmacokinetic and Pharmacodynamic Properties of Methadone
• Epidemiology, Modes of Transmission, & Risk Factors for Hepatitis C Virus (HCV) Infection
• Estimating Future Hepatitis C Morbidity, Mortality, and Costs in the United States
• Facing Hepatitis C, Info You Need (downloadable brochure)
• HALT-C Trial Shows Minimal Long-term Benefit of Pegylated Interferon Alfa-2a (Pegasys) Maintenance Therapy in Patients with Chronic Hepatitis C
• Hepatitis A
• Hepatitis B
• Herbs that may Harm the Liver
• Interferon Alpha Therapy for Hepatitis C: Treatment Completion and Response Rates Among Patients with Substance Use Disorders
• Medication and the Liver
• Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place
• National Institutes of Health: Consensus Development Conference Statement
  Management of Hepatitis C: 2002
  
• National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B
• New Directions in Hepatitis C Therapy: A Look at the Evolving Therapeutic Arsenal
• Ongoing Challenges in the Management of Chronic Hepatitis C
• Pain Killers and the Liver
• Successful Treatment of Chronic Hepatitis C with Pegylated Interferon in Combination with Ribavirin in a Methadone Maintenance Treatment Program
• Treatment for Co-occurring Substance Abuse and Hepatitis C
• Treating the Methadone Patient
• What's Cirrhosis?

Training Video

Glossary

Frequently Asked Questions

• Overview
  
• Statistics
  
• Transmission/Exposure
  
• Symptoms
  
• Tests
  
• Treatment
  
• Vaccination
  
• Miscellaneous

Links

• Government Agencies for Hepatitis & Substance Abuse Treatment
  
• Hepatitis Advocacy, Education & Services
  
• Substance Abuse Advocacy, Education & Services
  
• Pharmaceutical Services
  
• Clinical Trials
  
• Transplant Links